Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy <i>via</i> diminishing PD-L1 and promoting CD8<sup>+</sup> T cell-mediated ferroptosis in castration-resistant prostate cancer.

Zhou, Xumin; Zou, Libin; Liao, Hangyu; Luo, Junqi; Yang, Taowei; Wu, Jun; Chen, Wenbin; Wu, Kaihui; Cen, Shengren; Lv, Daojun; Shu, Fangpeng; Yang, Yu; Li, Chun; Li, Bingkun; Mao, Xiangming

Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8⁺ T cell-mediated ferroptosis in castration-resistant prostate cancer.

Zhou, Xumin; Zou, Libin; Liao, Hangyu; Luo, Junqi; Yang, Taowei; Wu, Jun; Chen, Wenbin; Wu, Kaihui; Cen, Shengren; Lv, Daojun; Shu, Fangpeng; Yang, Yu; Li, Chun; Li, Bingkun; Mao, Xiangming.

Afiliación

Zhou X; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Zou L; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Liao H; Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Luo J; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Yang T; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Wu J; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Chen W; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Wu K; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Cen S; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Lv D; Department of Urology, Minimally Invasive Surgery Center, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Shu F; Department of Urology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Yang Y; Department of Urology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Li C; Nursing Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Li B; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Mao X; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Acta Pharm Sin B ; 12(2): 692-707, 2022 Feb.

Article en En | MEDLINE | ID: mdl-35256940

Palabras clave

ADT, androgen deprivation therapy; Anti-PD-1 therapy; CRPC, castration-resistant prostate cancer; Castration-resistant prostate cancer; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; Fer-1, ferrostatin-1; Ferroptosis; GSH, glutathione; HnRNP L; HnRNP L, heterogeneous nuclear ribonucleoprotein L; IL, interleukin; INF-Î³, interferon gamma; Immune checkpoint blockade; Immune escape; PD-1, programmed cell death protein 1; PD-L1; PD-L1, programmed death ligand1; ROS, reactive oxygen species; STAT, signal transducer and activator of transcription; YY1; qRT-PCR, quantitative reverse transcription polymerase chain reaction

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Acta Pharm Sin B Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google